home / stock / cycc / cycc news

CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 11/11/20

Stock Information
Company Name: Cyclacel Pharmaceuticals Inc.
Stock Symbol: CYCC
Market: NASDAQ
Website: cyclacel.com
Menu
CYCC CYCC Quote CYCC Short CYCC News CYCC Articles CYCC Message Board
Get CYCC Alerts

News, Short Squeeze, Breakout and More Instantly...
CYCC - Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Eric Ando – Investor Relations Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President, Finance and Chief Opera...
CYCC - Cyclacel Pharmaceuticals EPS misses by $1.74

Cyclacel Pharmaceuticals (CYCC): Q3 GAAP EPS of -$2.27 misses by $1.74.Cash and equivalents totaled $23.1M, will fund currently planned programs through the end of 2022.Press Release For further details see: Cyclacel Pharmaceuticals EPS misses by $1.74

CYCC - Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third q...

CYCC - Cyclacel Pharmaceuticals to Release Third Quarter Financial Results

BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results on&...
CYCC - Cyclacel slides on fadraciclib data in early-stage solid tumor study

Cyclacel dips ([[CYCC]] -10.3%) on average volume as investors appear underwhelmed with data from a Phase 1 study evaluating fadraciclib for solid tumors. Data were presented at EORTC-NCI-AACR Symposium24 heavily pretreated patients with various advanced solid tu...

CYCC - Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020

BERKELEY HEIGHTS, N.J., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced clinical data demonstrating safety, anti-tum...

CYCC - Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer

BERKELEY HEIGHTS, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum, M....
CYCC - Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference

BERKELEY HEIGHTS, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company is scheduled to parti...

CYCC - Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020

BERKELEY HEIGHTS, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract highlighting clinical data...

CYCC - Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2020 Results - Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2020 Earnings Conference Call August 12, 2020 16:30 ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance & Chief Operating Offi...
Previous 10 Next 10